http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 15 May 2026 07:55:55 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/CapsoVision+%28CV%29+Reiterated+at+Speculative+Buy+by+Benchmark+After+Q1+Results/26499636.html <p>Benchmark analyst Bruce Jackson reiterated a Speculative Buy rating and $10.00 price target on CapsoVision Inc (NASDAQ: CV).</p><p>The analyst commented, " New product development programs remain on track, including 510(k) clearance of an AI-assisted reading feature for CapsoCam Plus (anticipated mid-year), submission of a 510(k) for CapsoCam Colon (anticipated 3Q 2026), and the initiation of a clinical study for CapsoCam UGI in pancreatic cancer detection (planned start date this month). Some orders slipped into April, which resulted in Q1 revenue of $2.8 million (flat year-over-year), but the renewal of key customer contracts with large GI networks (Indiana University Health Systems, http://www.streetinsider.com/Analyst+Comments/CapsoVision+%28CV%29+Reiterated+at+Speculative+Buy+by+Benchmark+After+Q1+Results/26499636.html Fri, 15 May 2026 07:55:55 -0400 CV http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CapsoVision%2C+Inc++++++++++For%3A+Mar+31/26495885.html si-local-file:///var/storage/secattach/20260514/26495885.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CapsoVision%2C+Inc++++++++++For%3A+Mar+31/26495885.html Thu, 14 May 2026 16:36:00 -0400 CV O.07041963 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CapsoVision%2C+Inc++++++++++For%3A+Mar+31/26495885.html si-local-file:///var/storage/secattach/20260514/26495885.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++CapsoVision%2C+Inc++++++++++For%3A+Mar+31/26495885.html Thu, 14 May 2026 16:36:00 -0400 CV O.07041963 http://www.streetinsider.com/Earnings/CapsoVision+%28CV%29+Misses+Q1+EPS+by+4c/26495410.html <p>CapsoVision (NASDAQ: CV) reported Q1 EPS of ($0.15), $0.04 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $2.8 million.</p><p>For earnings history and earnings-related data on CapsoVision (CV) <a href="http://www.streetinsider.com/ec_earnings.php?q=CV">click here</a>.</p> http://www.streetinsider.com/Earnings/CapsoVision+%28CV%29+Misses+Q1+EPS+by+4c/26495410.html Thu, 14 May 2026 16:21:38 -0400 CV http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CapsoVision%2C+Inc++++++++++For%3A+May+14/26494834.html si-local-file:///var/storage/secattach/20260514/26494834.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CapsoVision%2C+Inc++++++++++For%3A+May+14/26494834.html Thu, 14 May 2026 16:09:00 -0400 CV O.07041963 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CapsoVision%2C+Inc++++++++++For%3A+May+14/26494834.html si-local-file:///var/storage/secattach/20260514/26494834.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CapsoVision%2C+Inc++++++++++For%3A+May+14/26494834.html Thu, 14 May 2026 16:09:00 -0400 CV O.07041963 http://www.streetinsider.com/Press+Releases/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html <p align="justify">SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.</p> <p><strong>Recent Highlights</strong></p> <ul type="disc"><li style="margin-bottom:12pt;">Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.</li><li style="margin-bottom:12pt;">Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.</li><li style="margin-bottom:12pt;">Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health http://www.streetinsider.com/Press+Releases/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html Thu, 14 May 2026 16:05:00 -0400 A.22247716 CNNA CV O.05105698 O.05255286 O.07041963 http://www.streetinsider.com/Press+Releases/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html <p align="justify">SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.</p> <p><strong>Recent Highlights</strong></p> <ul type="disc"><li style="margin-bottom:12pt;">Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.</li><li style="margin-bottom:12pt;">Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.</li><li style="margin-bottom:12pt;">Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health http://www.streetinsider.com/Press+Releases/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html Thu, 14 May 2026 16:05:00 -0400 A.22247716 CNNA CV O.05105698 O.05255286 O.07041963 http://www.streetinsider.com/Press+Releases/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html <p align="justify">SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.</p> <p><strong>Recent Highlights</strong></p> <ul type="disc"><li style="margin-bottom:12pt;">Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.</li><li style="margin-bottom:12pt;">Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.</li><li style="margin-bottom:12pt;">Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health http://www.streetinsider.com/Press+Releases/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html Thu, 14 May 2026 16:05:00 -0400 A.22247716 CNNA CV O.05105698 O.05255286 O.07041963 http://www.streetinsider.com/Press+Releases/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html <p align="justify">SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.</p> <p><strong>Recent Highlights</strong></p> <ul type="disc"><li style="margin-bottom:12pt;">Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.</li><li style="margin-bottom:12pt;">Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.</li><li style="margin-bottom:12pt;">Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health http://www.streetinsider.com/Press+Releases/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html Thu, 14 May 2026 16:05:00 -0400 A.22247716 CNNA CV O.05105698 O.05255286 O.07041963 http://www.streetinsider.com/Press+Releases/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html <p align="justify">SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.</p> <p><strong>Recent Highlights</strong></p> <ul type="disc"><li style="margin-bottom:12pt;">Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.</li><li style="margin-bottom:12pt;">Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.</li><li style="margin-bottom:12pt;">Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health http://www.streetinsider.com/Press+Releases/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html Thu, 14 May 2026 16:05:00 -0400 A.22247716 CNNA CV O.05105698 O.05255286 O.07041963 http://www.streetinsider.com/Press+Releases/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html <p align="justify">SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.</p> <p><strong>Recent Highlights</strong></p> <ul type="disc"><li style="margin-bottom:12pt;">Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.</li><li style="margin-bottom:12pt;">Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.</li><li style="margin-bottom:12pt;">Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health http://www.streetinsider.com/Press+Releases/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html Thu, 14 May 2026 16:05:00 -0400 A.22247716 CNNA CV O.05105698 O.05255286 O.07041963 http://www.streetinsider.com/Globe+Newswire/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html <p align="justify">SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.</p> <p><strong>Recent Highlights</strong></p> <ul type="disc"><li style="margin-bottom:12pt;">Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.</li><li style="margin-bottom:12pt;">Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.</li><li style="margin-bottom:12pt;">Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health http://www.streetinsider.com/Globe+Newswire/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html Thu, 14 May 2026 16:05:00 -0400 A.22247716 CNNA CV O.05105698 O.05255286 O.07041963 http://www.streetinsider.com/Globe+Newswire/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html <p align="justify">SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.</p> <p><strong>Recent Highlights</strong></p> <ul type="disc"><li style="margin-bottom:12pt;">Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.</li><li style="margin-bottom:12pt;">Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.</li><li style="margin-bottom:12pt;">Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health http://www.streetinsider.com/Globe+Newswire/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html Thu, 14 May 2026 16:05:00 -0400 A.22247716 CNNA CV O.05105698 O.05255286 O.07041963 http://www.streetinsider.com/Globe+Newswire/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html <p align="justify">SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.</p> <p><strong>Recent Highlights</strong></p> <ul type="disc"><li style="margin-bottom:12pt;">Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.</li><li style="margin-bottom:12pt;">Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.</li><li style="margin-bottom:12pt;">Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health http://www.streetinsider.com/Globe+Newswire/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html Thu, 14 May 2026 16:05:00 -0400 A.22247716 CNNA CV O.05105698 O.05255286 O.07041963 http://www.streetinsider.com/Globe+Newswire/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html <p align="justify">SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.</p> <p><strong>Recent Highlights</strong></p> <ul type="disc"><li style="margin-bottom:12pt;">Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.</li><li style="margin-bottom:12pt;">Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.</li><li style="margin-bottom:12pt;">Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health http://www.streetinsider.com/Globe+Newswire/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html Thu, 14 May 2026 16:05:00 -0400 A.22247716 CNNA CV O.05105698 O.05255286 O.07041963 http://www.streetinsider.com/Globe+Newswire/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html <p align="justify">SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.</p> <p><strong>Recent Highlights</strong></p> <ul type="disc"><li style="margin-bottom:12pt;">Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.</li><li style="margin-bottom:12pt;">Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.</li><li style="margin-bottom:12pt;">Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health http://www.streetinsider.com/Globe+Newswire/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html Thu, 14 May 2026 16:05:00 -0400 A.22247716 CNNA CV O.05105698 O.05255286 O.07041963 http://www.streetinsider.com/Globe+Newswire/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html <p align="justify">SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for its first quarter ended March 31, 2026.</p> <p><strong>Recent Highlights</strong></p> <ul type="disc"><li style="margin-bottom:12pt;">Delivered first quarter revenue of $2.8 million, stable compared to the first quarter of 2025.</li><li style="margin-bottom:12pt;">Existing customers continued to expand clinical use of CapsoCam Plus® for small bowel disease detection, while procedure volume demonstrated growing adoption and end-user consumption.</li><li style="margin-bottom:12pt;">Secured key customer renewals with large GI networks, including Indiana University Health Systems, Providence Health http://www.streetinsider.com/Globe+Newswire/CapsoVision+Reports+First+Quarter+2026+Financial+Results/26494607.html Thu, 14 May 2026 16:05:00 -0400 A.22247716 CNNA CV O.05105698 O.05255286 O.07041963 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CapsoVision%2C+Inc+++++++++++++++++++++++Filed+by%3A+HARARI+ELIYAHOU+ET+AL/26445901.html si-local-file:///var/storage/secattach/20260506/26445901.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CapsoVision%2C+Inc+++++++++++++++++++++++Filed+by%3A+HARARI+ELIYAHOU+ET+AL/26445901.html Wed, 06 May 2026 19:01:00 -0400 CV O.07041963 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CapsoVision%2C+Inc+++++++++++++++++++++++Filed+by%3A+HARARI+ELIYAHOU+ET+AL/26445901.html si-local-file:///var/storage/secattach/20260506/26445901.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CapsoVision%2C+Inc+++++++++++++++++++++++Filed+by%3A+HARARI+ELIYAHOU+ET+AL/26445901.html Wed, 06 May 2026 19:01:00 -0400 CV O.07041963 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CapsoVision%2C+Inc++++++++++For%3A+May+04++Filed+by%3A+Atkinson+Douglas+Patrick/26442199.html si-local-file:///var/storage/secattach/20260506/26442199.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CapsoVision%2C+Inc++++++++++For%3A+May+04++Filed+by%3A+Atkinson+Douglas+Patrick/26442199.html Wed, 06 May 2026 12:51:00 -0400 CV O.07041963 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CapsoVision%2C+Inc++++++++++For%3A+May+04++Filed+by%3A+Atkinson+Douglas+Patrick/26442199.html si-local-file:///var/storage/secattach/20260506/26442199.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CapsoVision%2C+Inc++++++++++For%3A+May+04++Filed+by%3A+Atkinson+Douglas+Patrick/26442199.html Wed, 06 May 2026 12:51:00 -0400 CV O.07041963 http://www.streetinsider.com/Press+Releases/CapsoVision+to+Release+First+Quarter+2026+Financial+Results+on+May+14%2C+2026/26407499.html <p>SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release first quarter 2026 financial results on Thursday, May 14, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.</p> <p>Investors interested in listening to the conference call may do so by dialing (800) 715-9871 or (646) 307-1963 http://www.streetinsider.com/Press+Releases/CapsoVision+to+Release+First+Quarter+2026+Financial+Results+on+May+14%2C+2026/26407499.html Thu, 30 Apr 2026 16:05:00 -0400 CV O.07041963 http://www.streetinsider.com/Press+Releases/CapsoVision+to+Release+First+Quarter+2026+Financial+Results+on+May+14%2C+2026/26407499.html <p>SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release first quarter 2026 financial results on Thursday, May 14, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.</p> <p>Investors interested in listening to the conference call may do so by dialing (800) 715-9871 or (646) 307-1963 http://www.streetinsider.com/Press+Releases/CapsoVision+to+Release+First+Quarter+2026+Financial+Results+on+May+14%2C+2026/26407499.html Thu, 30 Apr 2026 16:05:00 -0400 CV O.07041963 http://www.streetinsider.com/Globe+Newswire/CapsoVision+to+Release+First+Quarter+2026+Financial+Results+on+May+14%2C+2026/26407499.html <p>SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release first quarter 2026 financial results on Thursday, May 14, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.</p> <p>Investors interested in listening to the conference call may do so by dialing (800) 715-9871 or (646) 307-1963 http://www.streetinsider.com/Globe+Newswire/CapsoVision+to+Release+First+Quarter+2026+Financial+Results+on+May+14%2C+2026/26407499.html Thu, 30 Apr 2026 16:05:00 -0400 CV O.07041963